Size | Price | Stock | Qty |
---|---|---|---|
5mg |
|
||
10mg |
|
||
25mg |
|
||
50mg |
|
||
100mg |
|
||
250mg |
|
||
500mg |
|
||
Other Sizes |
|
Purity: ≥98%
RETV804M kinase inhibitor (Compound 13) is a novel and potent inhibitor of RETV804M kinase, which is the anticipated drug-resistant mutant of RET kinase. It provides a potential supplement to RET inhibitors that are presently undergoing clinical evaluation because it does not inhibit the wild type (wt) isoforms of RET or KDR.
Targets |
RETV804M (IC50 = 20 nM)
|
---|---|
ln Vitro |
RET V804M-IN-1 (compound 5) exhibits 110 fold selectivity and 3.7 fold selectivity in comparison to wt-RET and KDR, respectively[1].
|
References |
Molecular Formula |
C19H16N6O
|
---|---|
Molecular Weight |
344.38
|
Exact Mass |
344.14
|
Elemental Analysis |
C, 66.27 H, 4.68 N, 24.40 O, 4.65
|
CAS # |
2414909-94-5
|
Related CAS # |
2414909-94-5
|
PubChem CID |
145994823
|
Appearance |
Off-white to light yellow solid powder
|
Density |
1.38±0.1 g/cm3(Predicted)
|
LogP |
1.6
|
Hydrogen Bond Donor Count |
2
|
Hydrogen Bond Acceptor Count |
5
|
Rotatable Bond Count |
5
|
Heavy Atom Count |
26
|
Complexity |
481
|
Defined Atom Stereocenter Count |
0
|
SMILES |
O=C(C1C=CC(C2C=NN3C=CC(NCC4C=NC=CC=4)=NC=23)=CC=1)N
|
InChi Key |
LMGXQBQAUALFTB-UHFFFAOYSA-N
|
InChi Code |
InChI=1S/C19H16N6O/c20-18(26)15-5-3-14(4-6-15)16-12-23-25-9-7-17(24-19(16)25)22-11-13-2-1-8-21-10-13/h1-10,12H,11H2,(H2,20,26)(H,22,24)
|
Chemical Name |
4-[5-(pyridin-3-ylmethylamino)pyrazolo[1,5-a]pyrimidin-3-yl]benzamide
|
Synonyms |
LUN 09945; LUN09945; LUN-09945
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
DMSO: ~125 mg/mL (~363.0 mM)
|
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (6.04 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (6.04 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (6.04 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 2.9038 mL | 14.5188 mL | 29.0377 mL | |
5 mM | 0.5808 mL | 2.9038 mL | 5.8075 mL | |
10 mM | 0.2904 mL | 1.4519 mL | 2.9038 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.